IGF-1 splice variant peptide
PEG-MGF (Pegylated Mechano Growth Factor)
PEG-MGF has no half-life reported in a 2026 review of GH-IGF-1 axis peptides, and the app lists 72 hours.1
PEG-MGF (Pegylated Mechano Growth Factor) after one dose: 50% at ~72 h, 25% at 144 h, 12.5% at 216 h.
Drawn from the half-life in the app's model, ~72 h. The model's figures
- Compound
- PEG-MGF (Pegylated Mechano Growth Factor)
- Symbol
- PEG
- Family
- Growth hormone peptides
- Parts
- 12
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
PEG-MGF is described by a 2026 review in Frontiers in Endocrinology (Dominikowski and colleagues) as "marketed as a PEGylated form of mechano-growth factor (MGF)".1 In physiological terms, the same review states that MGF corresponds to an IGF-1 splice variant, often called IGF-1Ec.1 Matheny and colleagues, Endocrinology, 2010, write that a synthetic peptide called MGF corresponds to "the 24 most C-terminal residues of IGF-IEb", and that "no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or in vivo animal tissues or biological fluids".2 The Dominikowski review places PEG-MGF in its lowest evidence tier, one with "no peer-reviewed human studies" and support only from preclinical extrapolation and grey-literature user narratives.1 The app grades the evidence for PEG-MGF as anecdotal.
How it works
The Dominikowski review states that IGF-1 analogues "act primarily through the IGF-1R, a transmembrane receptor with intrinsic tyrosine kinase activity", and its table lists PEG-MGF's mechanism as IGF-1R tyrosine kinase signaling and satellite cell proliferation, described preclinically.1 The review adds that the rationale for PEGylation "as promoted commercially" is to increase molecular stability and prolong exposure, but that the mechanistic literature cited for MGF-like effects is largely based on IGF-1Ec/MGF biology and synthetic E-domain peptide constructs, "rather than on PEG-MGF as a clinically characterised drug entity".1 It also states that "biological effects observed with native IGF-1Ec or isolated E-domain peptides cannot be assumed to apply to PEG-conjugated constructs".1 The laboratory results below are therefore results for the MGF E-domain peptide, not for PEG-MGF.
In human primary muscle cell cultures, Ates and colleagues (University College London, FEBS Letters, 2007) reported that "the E domain peptide of IGF-IEc (MGF) significantly increased the numbers of progenitor cells in healthy and diseased muscle".3 Kandalla and colleagues (Institut de Myologie, Paris, Mechanisms of Ageing and Development, 2011) reported that the MGF-E peptide increased the proliferative life span of satellite cells from neonatal and young adult muscle "but not from old adult muscle".4 Fornaro and colleagues (first author at Novartis Institutes for Biomedical Research, with the work done "at our two pharmaceutical companies"; American Journal of Physiology Endocrinology and Metabolism, 2014) could not reproduce a proliferative effect: "Concentrations of peptide up to 500 ng/ml failed to increase the proliferation of C2C12 cells or primary human skeletal muscle myoblasts."5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~72 h
- Bioavailability
- 70%
- Typical dose
- 200–500 mcg/dose
- Route
- SubQ
- Time to peak
- ~4 h
Sources in this part
The second column holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~72 h | Not reported: the Dominikowski review lists "t½ not reported" for PEG-MGF1 |
| Bioavailability | 70% | No figure for PEG-MGF in the sources read1 |
| Time to peak | ~4 h | No figure for PEG-MGF in the sources read1 |
| Duration | 72 h | No figure for PEG-MGF in the sources read1 |
| Route | SubQ | "No peer-reviewed clinical studies in humans have reported the route of administration"; forum reports cited in the review give subcutaneous or intramuscular1 |
The review states that "PEGylation fundamentally alters pharmacokinetics and tissue exposure".1 No pharmacokinetic study of PEG-MGF in people or animals was identified in the PubMed searches "PEG-MGF", "pegylated mechano growth factor" and "PEGylated MGF", which returned 1, 5 and 3 records, none of them such a study.
Human studies
No controlled trial of PEG-MGF in people was identified in the PubMed searches above or in ClinicalTrials.gov, where the search "mechano growth factor" returned 499 registry entries and none of the first 20 listed was a PEG-MGF or MGF study. The Dominikowski review states "No peer-reviewed human studies" for PEG-MGF in its table and that "robust RCTs in human populations are lacking".1 Its authors report no external funding and no commercial or financial relationships that could be construed as a conflict of interest.1
The table lists laboratory studies of MGF peptides in cell cultures, not in people.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ates and colleagues, FEBS Letters 20073 | Laboratory study of splice variant peptides on proliferation and differentiation; grant: Wellcome Trust | Human primary muscle cell cultures from healthy subjects and from muscular dystrophy and ALS patients (cell donors; n not given in the PubMed record) | Not given in the PubMed record | MGF E peptide increased progenitor cell numbers in healthy and diseased muscle; IGF-I enhanced differentiation whereas MGF E peptide blocked it |
| Kandalla and colleagues, Mechanisms of Ageing and Development 20114 | Laboratory study of the MGF-24aa-E peptide on proliferation and differentiation | Primary human muscle cell cultures from healthy subjects of different ages (cell donors; n not given in the PubMed record) | Not given in the PubMed record | Increased proliferative life span and delayed senescence in satellite cells from neonatal and young adult but not old adult muscle; hypertrophy with fewer reserve cells in all cultures |
| Fornaro and colleagues, American Journal of Physiology Endocrinology and Metabolism 20145 | Attempt to reproduce claimed MGF peptide effects in vitro, at two pharmaceutical companies | C2C12 mouse cells, primary human skeletal muscle myoblasts, primary mouse muscle stem cells | Peptide up to 500 ng/ml; native and stabilized MGF peptide | No increase in proliferation and no inhibition of differentiation; "no demonstrated activating responses from the native or a stabilized MGF peptide"; IGF-1 and full-length IGF-1Eb did increase proliferation |
Deeper analysis: Fornaro and colleagues, 2014
Fornaro and colleagues wrote that, "at our two pharmaceutical companies", they tried to reproduce claimed effects of MGF peptides on human and mouse muscle myoblasts.5 The MGF peptide also failed to inhibit differentiation of myoblasts into myotubes, and primary mouse skeletal muscle stem cells showed no significant effect.5 The authors concluded that the results "call in to question whether there is a physiological role for MGF".5 The first listed author is affiliated with Novartis Institutes for Biomedical Research, Basel, and the paper's text names pharmaceutical companies as the sites of the work; no funding statement appears in the PubMed record.5 Only the PubMed record was read, so the authors' own discussion of limitations is not reported here.
Deeper analysis: Ates and colleagues, 2007
Ates and colleagues compared splice variant peptides in human primary muscle cultures and found that although initial numbers of progenitor cells expressing desmin were lower in diseased muscle, the MGF E peptide increased progenitor numbers in healthy and diseased muscle.3 The authors conclude that MGF E peptide blocks the differentiation pathway that IGF-I enhances, "resulting in an increased progenitor (stem) cell pool and thus potentially facilitating repair and maintenance of this postmitotic tissue".3 The PubMed record lists the Wellcome Trust as grant source and Goldspink G among nine authors; it states no sponsor tie beyond that, and gives no limitations.3 The record describes the E domain peptide of IGF-IEc and does not mention PEGylation.3
Deeper analysis: Kandalla and colleagues, 2011
Kandalla and colleagues studied the MGF-24aa-E peptide in primary human muscle cell cultures from healthy subjects of different ages.4 They concluded that the peptide "alone has a marked ability to enhance satellite cell activation, proliferation and fusion for muscle repair and maintenance" and "could provide a new strategy to combat age related sarcopenia without the oncogenic side effects observed for IGF1".4 The PubMed record gives the publication type "Research Support, Non-U.S. Gov't", names no grant, and lists Goldspink G among four authors; the increase in proliferative life span was reported for satellite cells from neonatal and young adult muscle "but not from old adult muscle".4 The statement about oncogenic side effects is the authors' conclusion from cell cultures, and the record does not report an oncogenicity test.4
Doses reported in studies and on labels
Sources in this part
No label for PEG-MGF and no dose from a clinical study were identified; the Dominikowski review states that "No peer-reviewed clinical studies currently report specific dosing regimens in humans".1 The table gives what the review summarised from bodybuilding-related online forums, which it describes as "non−peer−reviewed, often internally inconsistent online protocols".1
| Source | Reported regimen | Reference |
|---|---|---|
| Bodybuilding-related forums, as summarised by the Dominikowski review | Subcutaneous or intramuscular 200–400 µg 2–3 times a week after training; loading sequence 100 µg for 2 weeks, 200 µg for 2 weeks, 300 µg for 4 weeks; maintenance 200–400 µg a day; cycles of 8 to 16 weeks with about 4 weeks off1 | Dominikowski 2026 |
| The app's figure | 200–500 mcg/dose, subcutaneous | The app (no figure from a label or study) |
The review states that these values "MUST NOT be interpreted as clinically validated, regulatory−approved, or safe for use".1
Side effects reported
Sources in this part
No peer-reviewed human study of PEG-MGF reports adverse events, according to the Dominikowski review.1 The review lists a "theoretical proliferative concern based on IGF-1Ec (MGF) expression in cancer biology (preclinical evidence)".1 It states that forum reports of "local-only action" and an absence of systemic adverse effects are anecdotal and "cannot substitute for controlled safety or efficacy data".1 For IGF-1 analogues as a class, the review describes chronic IGF-1 elevation as the central long-term concern and notes that long-term cancer risk "cannot be inferred directly from short-term exposure".1
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List places "Mechano growth factors (MGFs)" in S2.3, growth factors and growth factor modulators, within a class that is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".6 The text of the list as read does not name PEG-MGF separately; the S2 class also covers "other substances with similar chemical structure or similar biological effect(s)".6 Thevis and colleagues (Growth Hormone and IGF Research, 2014) write that MGF "has been considered prohibited according to the regulations of the World Anti-Doping Agency (WADA) since 2005".7 The same group characterised a product sold as "full-length MGF" with a monoisotopic mass of 12264.9 Da and detected it at 0.25 ng/mL with adapted routine doping-control methods.7 That work concerned a full-length MGF protein, not PEG-MGF; the PubMed record gives the publication type "Research Support, Non-U.S. Gov't" and names no funder.7
In the United States, the FDA's 503A bulk drug substances list, updated 14 May 2026, names six substances in Category 2 (Cesium Chloride, Domperidone, Germanium Sesquioxide, Ibutamoren Mesylate, Kisspeptin-10 and Quinacrine Hydrochloride for intrauterine administration), and PEG-MGF is not among them.8 The same list names "Mechano growth factor (MGF)", not PEG-MGF, in Category 3, bulk drug substances nominated without adequate support; the list text read does not name PEG-MGF in any category.8 The Frier Levitt law firm lists "Mechano Growth Factor, Pegylated (PEG-MGF)" among twelve peptide substances being removed from Category 2 "as their nominations have been withdrawn by the respective nominators".9 The same article states that "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A".9 It lists PEG-MGF among substances "not scheduled for consideration at the upcoming meeting in July" that "are slated for separate PCAC consultation before the end of February 2027".9 The app's note says a July 2026 FDA meeting will explore a full approval pathway; the law firm's article instead places PEG-MGF outside that July meeting, and none of the sources read describes an approval pathway for PEG-MGF.9
What is not known
No human pharmacokinetic, efficacy or safety study of PEG-MGF was identified in the searches described above. The half-life, bioavailability, time to peak and duration the app lists for PEG-MGF were not matched by any figure in the sources read.1 Whether the MGF E peptide has a physiological role is disputed in the cell studies read: Ates reported increased progenitor cell numbers, Kandalla reported increased proliferative life span in satellite cells from neonatal and young adult but not old adult muscle, and Fornaro reported no increase in proliferation.3,4,5 Matheny and colleagues state that no matching peptide product of the Igf1 gene has been identified in tissues or fluids examined to 2010.2 Whether laboratory results on the MGF E peptide carry over to a PEGylated product is not established, because the review states that they "cannot be assumed to apply to PEG-conjugated constructs".1
Frequently asked questions
Has PEG-MGF been tested in human trials?
No controlled trial of PEG-MGF in people was identified in PubMed or ClinicalTrials.gov searches run on 16 November 2026. The Dominikowski review states "No peer-reviewed human studies" for PEG-MGF.1
What does research on the MGF peptide show in muscle cells?
Ates and colleagues reported that the MGF E peptide "significantly increased the numbers of progenitor cells in healthy and diseased muscle" in human cell cultures.3 Fornaro and colleagues reported that peptide concentrations up to 500 ng/ml "failed to increase the proliferation" of C2C12 cells or primary human skeletal muscle myoblasts.5
What is the bioavailability of PEG-MGF?
The app lists a bioavailability of 70%, and none of the sources read gives a figure for PEG-MGF.1
Guides, tools and comparisons
References
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026;17:1822475. PMC13322892
- Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010;151(3):865-75. PMC2840678
- Ates K, et al. The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Lett 2007;581(14):2727-32. PMID 17531227
- Kandalla PK, et al. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev 2011;132(4):154-62. PMID 21354439
- Fornaro M, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 2014;306(2):E150-6. PMID 24253050
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Thevis M, Thomas A, Geyer H, Schänzer W. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Horm IGF Res 2014;24(6):276-80. PMID 25466910
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, updated 14 May 2026. FDA 503A bulks list
- Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List. Law firm article, 2026. Frier Levitt article